1. Home
  2. Labeler Index
  3. Sun Pharmaceutical Industries, Inc.
  4. 47335-187
  5. NDC Package Code: 47335-187-08 Carbidopa And Levodopa

NDC Package 47335-187-08 Carbidopa And Levodopa

Tablet, Orally Disintegrating Oral - View Billable Units, 11-Digit Format, RxNorm

Table of Contents

    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
47335-187-08
Package Description:
100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE
Product Code:
47335-187
Proprietary Name:
Carbidopa And Levodopa
Non-Proprietary Name:
Carbidopa And Levodopa
Substance Name:
Carbidopa; Levodopa
Usage Information:
Carbidopa and levodopa orally disintegrating tablets are indicated in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. Carbidopa and levodopa orally disintegrating tablets are indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response, and with supplemental pyridoxine (vitamin B6).In some patients, a somewhat smoother antiparkinsonian effect results from therapy with carbidopa and levodopa than with levodopa. However, patients with markedly irregular (“on-off”) responses to levodopa have not been shown to benefit from carbidopa and levodopa therapy.Although the administration of carbidopa permits control of parkinsonism and Parkinson’s disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa.Certain patients who responded poorly to levodopa have improved when carbidopa and levodopa was substituted. This is most likely due to decreased peripheral decarboxylation of levodopa which results from administration of carbidopa rather than to a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa in parkinsonian syndromes.In considering whether to give carbidopa and levodopa orally disintegrating tablets to patients already on levodopa who have nausea and/or vomiting, the practitioner should be aware that, while many patients may be expected to improve, some do not. Since one cannot predict which patients are likely to improve, this can only be determined by a trial of therapy. It should be further noted that in controlled trials comparing carbidopa and levodopa with levodopa, about half of the patients with nausea and/or vomiting on levodopa improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial.
11-Digit NDC Billing Format:
47335018708
NDC to RxNorm Crosswalk:
  • RxCUI: 476399 - carbidopa 25 MG / levodopa 100 MG Disintegrating Oral Tablet
  • RxCUI: 476399 - Carbidopa 25 MG / L-DOPA 100 MG Disintegrating Oral Tablet
  • RxCUI: 476515 - carbidopa 25 MG / levodopa 250 MG Disintegrating Oral Tablet
  • RxCUI: 476515 - Carbidopa 25 MG / L-DOPA 250 MG Disintegrating Oral Tablet
  • RxCUI: 483090 - carbidopa 10 MG / levodopa 100 MG Disintegrating Oral Tablet
    • Product Type:
    Human Prescription Drug
    Labeler Name:
    Sun Pharmaceutical Industries, Inc.
    Dosage Form:
    Tablet, Orally Disintegrating - A solid dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue.
    Administration Route(s):
  • Oral - Administration to or by way of the mouth.
    • Active Ingredient(s):
  • CARBIDOPA 25 mg/1
  • LEVODOPA 100 mg/1
    • Pharmacologic Class(es):
  • Amino Acids, Aromatic - [CS]
  • Aromatic Amino Acid - [EPC] (Established Pharmacologic Class)
    • Sample Package:
    No
    FDA Application Number:
    ANDA078690
    Marketing Category:
    ANDA - A product marketed under an approved Abbreviated New Drug Application.
    Start Marketing Date:
    12-15-2014
    Listing Expiration Date:
    12-31-2024
    Exclude Flag:
    N
    Code Structure:

    The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

    * Please review the disclaimer below.

    Other Product Packages

    The following packages are also available for this product:

    NDC Package CodePackage Description
    47335-187-181000 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE
    47335-187-8330 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE
    47335-187-88100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE

    * Please review the disclaimer below.

    Frequently Asked Questions

    What is NDC 47335-187-08?

    The NDC Packaged Code 47335-187-08 is assigned to a package of 100 tablet, orally disintegrating in 1 bottle of Carbidopa And Levodopa, a human prescription drug labeled by Sun Pharmaceutical Industries, Inc.. The product's dosage form is tablet, orally disintegrating and is administered via oral form.

    Is NDC 47335-187 included in the NDC Directory?

    Yes, Carbidopa And Levodopa with product code 47335-187 is active and included in the NDC Directory. The product was first marketed by Sun Pharmaceutical Industries, Inc. on December 15, 2014 and its listing in the NDC Directory is set to expire on December 31, 2024 if the product is not updated or renewed by the manufacturer.

    What is the 11-digit format for NDC 47335-187-08?

    The 11-digit format is 47335018708. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

    This package code is originally configured in a 5-3-2 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

    10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
    5-3-247335-187-085-4-247335-0187-08